S. Hegewisch-Becker

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

Dominik Paul Modest, Ingrid Ricard, Volker Heinemann et al. · Annals of Oncology · 2016 · 334 citations · Full text

Blood‐based detection of <i><scp>RAS</scp></i> mutations to guide anti‐<scp>EGFR</scp> therapy in colorectal cancer patients: concordance of results from circulating tumor <scp>DNA</scp> and tissue‐based <i><scp>RAS</scp></i> testing

Wolff Schmiegel, Rodney J. Scott, S Dooley et al. · Molecular Oncology · 2017 · 159 citations · Full text

Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients

Jens Panse, Kay Friedrichs, Alexander Marx et al. · British Journal of Cancer · 2008 · 125 citations · Full text

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

Stefan Kubicka, Richard Greil, Thierry André et al. · Annals of Oncology · 2013 · 101 citations · Full text

Gastrointestinal Oncology, Medicine, Pathology +8

Trastuzumab in combination with 5‐fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2‐positive locally advanced esophagogastric adenocarcinoma: A phase <scp>II</scp> trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group

Ralf‐Dieter Hofheinz, S. Hegewisch-Becker, Volker Kunzmann et al. · International Journal of Cancer · 2021 · 95 citations · Full text